JTO Clinical and Research Reports (Nov 2021)

CADM1 and SPC25 Gene Mutations in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis

  • Aya Fukuizumi, MD,
  • Rintaro Noro, MD, PhD,
  • Masahiro Seike, MD, PhD,
  • Akihiko Miyanaga, MD, PhD,
  • Yuji Minegishi, MD, PhD,
  • Miwako Omori, MD,
  • Mamiko Hirao,
  • Kuniko Matsuda,
  • Shinobu Kunugi, MD, PhD,
  • Kazutaka Nishiwaki,
  • Masahiro Morimoto,
  • Haruka Motohashi,
  • Hayato Ohwada, PhD,
  • Jitsuo Usuda, MD, PhD,
  • Akihiko Gemma, MD, PhD

Journal volume & issue
Vol. 2, no. 11
p. 100232

Abstract

Read online

Introduction: To investigate the genomic profiles of patients with lung cancer with idiopathic pulmonary fibrosis (IPF-LC), mechanism of carcinogenesis, and potential therapeutic targets. Methods: We analyzed 29 matched, surgically resected, cancerous and noncancerous lung tissues (19 IPF-LC and 10 non–IPF-LC) by whole-exome sequencing and bioinformatics analysis and established a medical-engineering collaboration with the Department of Engineering of the Tokyo University of Science. Results: In IPF-LC, CADM1 and SPC25 were mutated at a frequency of 47% (9 of 19) and 53% (10 of 19), respectively. Approximately one-third of the IPF-LC cases (7 of 19; 36%) had both mutations. Pathway analysis revealed that these two genes are involved in transforming growth factor-β1 signaling. CADM1 and SPC25 gene mutations decreased the expression of CADM1 and increased that of SPC25 revealing transforming growth factor-β1–induced epithelial-to-mesenchymal transition and cell proliferation in lung cancer cells. Furthermore, treatment with paclitaxel and DNMT1 inhibitor suppressed SPC25 expression. Conclusions: CADM1 and SPC25 gene mutations may be novel diagnostic markers and therapeutic targets for IPF-LC.

Keywords